Latest Ratios: P/E Ratio 45.3x · EV/EBITDA 21.2x · ROE 21.4%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.8B | $1.8B | $827M | $289M | $184M | $224M | $153M | $138M | $67M | $86M | $43M |
| Enterprise Value | $3.0B | $2.0B | $960M | $487M | $327M | $288M | $234M | $114M | $51M | $79M | $-31713860 |
| P/E Ratio → | 45.31 | 28.81 | 21.68 | 64.46 | 14.32 | 39.76 | 95.13 | — | — | — | — |
| P/S Ratio | 3.37 | 2.17 | 1.13 | 0.48 | 0.44 | 0.67 | 0.51 | 0.42 | 0.21 | 0.26 | 0.12 |
| P/B Ratio | 8.68 | 5.52 | 3.18 | 1.28 | 0.85 | 1.19 | 0.87 | 1.21 | 0.53 | 0.68 | 0.32 |
| P/FCF | 50.89 | 32.70 | 13.42 | — | — | — | 86.43 | 9.05 | — | — | — |
| P/OCF | 28.94 | 18.60 | 9.63 | 5.88 | 3.99 | 4.06 | 13.87 | 6.36 | — | — | 5.86 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.35 | 1.31 | 0.80 | 0.78 | 0.86 | 0.78 | 0.34 | 0.16 | 0.24 | -0.09 |
| EV / EBITDA | 21.17 | 13.99 | 8.72 | 7.25 | 5.93 | 6.47 | 6.71 | 11.98 | — | 4.82 | -67.76 |
| EV / EBIT | 35.57 | 21.82 | 14.61 | 17.55 | 14.69 | 18.64 | — | — | — | 121.16 | — |
| EV / FCF | — | 35.44 | 15.58 | — | — | — | 132.16 | 7.43 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.7% | 49.7% | 47.5% | 45.7% | 50.5% | 50.2% | 48.2% | 46.2% | 42.4% | 44.2% | 44.0% |
| Operating Margin | 10.0% | 10.0% | 8.0% | 3.5% | 5.3% | 4.5% | -0.9% | -2.4% | -11.1% | -0.6% | -5.4% |
| Net Profit Margin | 7.5% | 7.5% | 5.7% | 2.0% | 6.2% | 4.4% | 2.7% | -2.4% | -10.3% | -2.5% | -13.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.4% | 21.4% | 17.3% | 5.6% | 12.8% | 8.0% | 5.5% | -6.5% | -25.9% | -6.2% | -38.1% |
| ROA | 8.0% | 8.0% | 5.7% | 1.9% | 4.9% | 3.1% | 2.2% | -2.8% | -11.7% | -2.8% | -16.7% |
| ROIC | 14.3% | 14.3% | 10.8% | 4.1% | 5.5% | 4.4% | -1.1% | -5.8% | -23.1% | -1.5% | -14.7% |
| ROCE | 14.7% | 14.7% | 10.8% | 4.4% | 5.6% | 4.3% | -1.0% | -4.3% | -18.7% | -0.9% | -9.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.85 | 1.13 | 1.55 | 0.97 | 1.05 | 0.89 | 0.36 | 0.33 | 0.34 | 0.32 |
| Debt / EBITDA | 1.99 | 1.99 | 2.68 | 5.20 | 3.80 | 4.44 | 4.53 | 4.29 | — | 2.64 | 94.13 |
| Net Debt / Equity | — | 0.46 | 0.51 | 0.88 | 0.67 | 0.34 | 0.46 | -0.22 | -0.13 | -0.06 | -0.55 |
| Net Debt / EBITDA | 1.08 | 1.08 | 1.21 | 2.95 | 2.60 | 1.44 | 2.32 | -2.61 | — | -0.43 | -160.24 |
| Debt / FCF | — | 2.74 | 2.16 | — | — | — | 45.74 | -1.62 | — | — | — |
| Interest Coverage | 15.96 | 15.96 | 6.94 | 2.87 | 11.11 | 42.36 | -258.40 | -1.38 | -9.78 | 0.19 | -5.26 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | 1.07 | 1.08 | 1.11 | 0.99 | 1.38 | 1.48 | 1.22 | 1.26 | 1.70 | 1.71 |
| Quick Ratio | 1.07 | 1.07 | 1.08 | 1.11 | 0.92 | 1.38 | 1.48 | 0.99 | 1.00 | 2.16 | 1.71 |
| Cash Ratio | 0.74 | 0.74 | 0.79 | 0.82 | 0.69 | 1.01 | 0.94 | 0.68 | 0.63 | 1.13 | 1.28 |
| Asset Turnover | — | 1.01 | 0.98 | 0.82 | 0.76 | 0.65 | 0.68 | 1.23 | 1.12 | 1.18 | 1.17 |
| Inventory Turnover | — | — | — | — | 21.40 | — | — | 8.04 | 7.49 | — | — |
| Days Sales Outstanding | — | 23.01 | 18.58 | 18.72 | 19.25 | 24.71 | 49.27 | 25.50 | 30.27 | 17.11 | 16.04 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 0.1% | 1.8% | 2.8% | 2.3% | 0.1% | 1.0% | 1.7% | 6.1% | 3.4% |
| Payout Ratio | — | — | — | — | — | — | 1.2% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.2% | 3.5% | 4.6% | 1.6% | 7.0% | 2.5% | 1.1% | — | — | — | — |
| FCF Yield | 2.0% | 3.1% | 7.4% | — | — | — | 1.2% | 11.1% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.4% | 0.3% | 0.4% | 0.2% | 0.0% | 0.5% | 0.3% | 0.7% | 0.9% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.5% | 2.0% | 3.2% | 2.5% | 0.1% | 1.4% | 2.0% | 6.8% | 4.3% |
| Shares Outstanding | — | $56M | $51M | $34M | $34M | $33M | $30M | $25M | $25M | $25M | $24M |
Regulatory Title IV dependency
According to current market data, UTI trades at a forward P/E of 53.71, which appears significantly disconnected from the company's recent earnings volatility and the decelerating revenue growth observed in 2026Q2, suggesting that investors may be pricing in a recovery that has yet to materialize in the financials.
The high forward multiple implies an expectation of rapid margin expansion that contradicts the recent compression in operating margins to near-zero levels. Investors should monitor whether this premium is based on the platform value of the Concorde acquisition or if it represents an overestimation of the company's ability to scale its high-fixed-cost model.
Based on reported figures, UTI's ROIC has trended toward 0.0% in 2026Q2, a sharp decline from the 5.2% peak in 2025Q1, indicating that the company is currently failing to generate returns on its invested capital that exceed its likely cost of capital in the current environment.
The decay in ROIC suggests that the capital-intensive nature of the Concorde integration and ongoing lab investments are not yet yielding the expected incremental returns. This trend warrants further investigation into whether the company's asset base is becoming bloated relative to its current student enrollment capacity.
As reported in recent financial statements, UTI's asset turnover has remained stagnant at approximately 0.26, which, when combined with the volatility in DSO, suggests that the company is struggling to optimize its working capital cycle amidst the integration of diverse healthcare and industrial educational segments.
The inability to improve asset turnover despite revenue growth indicates that the company's infrastructure is not being utilized with increasing efficiency. This lack of operational leverage suggests that management may face challenges in scaling the business without proportional increases in facility and instructional overhead.
Based on the latest quarterly filings, UTI's interest coverage ratio has plummeted to 0.11 in 2026Q2 from a high of 29.12 in 2025Q4, signaling that the company's ability to service its debt obligations has become significantly more constrained as operating income has evaporated.
While the debt-to-equity ratio of 0.86 appears manageable in isolation, the collapse in interest coverage suggests that the company's current earnings profile is insufficient to provide a comfortable buffer for debt service. This shift indicates that the balance sheet, while historically conservative, is becoming increasingly vulnerable to operational shocks.
The P/E ratio is frequently misapplied to UTI, as it obscures the significant impact of non-recurring integration costs and the high depreciation associated with lab-intensive assets, which often distort net income and make the company appear more or less profitable than its underlying cash-generating capacity suggests.
Analysts should instead focus on EV/EBITDA or P/FCF to better capture the true operational performance of the business, as these metrics normalize for the capital structure and the heavy non-cash charges inherent in the vocational education model. Relying on P/E in this context may lead to a fundamental misunderstanding of the company's actual cash-flow-generating potential.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UTI stock.
Universal Technical Institute, Inc.'s current P/E ratio is 45.3x. The historical average is 43.0x. This places it at the 71th percentile of its historical range.
Universal Technical Institute, Inc.'s current EV/EBITDA is 21.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.2x.
Universal Technical Institute, Inc.'s return on equity (ROE) is 21.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 9.3%.
Based on historical data, Universal Technical Institute, Inc. is trading at a P/E of 45.3x. This is at the 71th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Universal Technical Institute, Inc. has 49.7% gross margin and 10.0% operating margin.
Universal Technical Institute, Inc.'s Debt/EBITDA ratio is 2.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.